Coherus Oncology, Inc. - 8-K Filing
Coherus Oncology reports Q3 2026 net revenue of $14.3 million and announces strategic prioritization plan to focus on esophageal cancer development. (Items: 2.02 Results of Operations and Financial Conditions, 9.01 Financial Statements and Exhibits)
Tickers: $CHRS
Read the full article at SEC EDGAR
Part of the story National CineMedia, Inc. - 8-K Filing (9 articles)